1. Field of the Invention
The invention relates generally to devices that can be inserted in and attached to a living being for the purpose of facilitating the introduction of a fluid, such as medicine, into the living being. The invention also relates to systems that include one or more such devices, and to methods of delivering fluid into a living being.
2. Description of Related Art
Examples of devices that can be used to deliver fluids to a living being include: U.S. Pat. Nos. 4,755,173; 4,966,588; 5,968,011; 6,017,328; 6,056,718; 6,074,371; 6,685,674; 6,736,797; U.S. Patent Application Pub. Nos. 2002/0072720; 2004/0006316; 2005/0101910; 2005/0107743; and abandoned Ser. No. 09/110,360 (incorporated by reference in U.S. Pat. No. 6,074,371).
Some embodiments of the present fluid delivery devices, systems and methods may be used to deliver fluid such as insulin to users such as people with diabetes. Some embodiments of the present fluid delivery devices may be configured to be worn for an extended period of time (e.g., multiple days) and allow a user to inject a fluid (such as a physician-prescribed drug) into the user's body without the need to repeatedly puncture the user's skin with a needle. The present fluid delivery devices, systems and methods include many different features that distinguish them from prior devices, and certain of those features are different in many ways from the features of prior devices. Different embodiments of the present fluid delivery devices, systems and methods include one or more of these features, which are interchangeable between embodiments to the extent that they are not inconsistent with the other features of a given embodiment.
Some embodiments of the present fluid delivery devices include, broadly, a body, a cannula, a needle guide, and a septum. The body may be made from one or more pieces, such as two pieces. The body may include one or more fluid delivery passageways. One or more of the fluid delivery passageways may be oriented at a non-parallel angle to the normal direction of installation of the device. In some embodiments that include two or more fluid delivery passageways, one the of the passageways may extend into and be angled with respect to another. In some multi-fluid delivery passageway embodiments, the devices also may include a passageway closing structure that at least partially blocks one of the passageways in a first position and another of the passageways in a second position. The passageway or passageways that are not blocked in a given position may remain at least partially unobstructed and, more preferably, substantially unobstructed. In some embodiments, the passageway closing structure may be actuated or shifted between positions by an injection device, such as an injection needle. In some multi-fluid delivery passageway embodiments, some or all of the fluid delivery passageways may be defined in part by a fitting adapted to be releasably coupled to an infusion pump connector fitting. Thus, in such embodiments, the device may allow for fluid delivery from a pump and fluid delivery from another structure, such as a syringe.
The cannula and the body of the devices may be integrally formed, such that the cannula comprises a tube-like structure that extends outwardly from the body (e.g., from the bottom surface of the body). The devices also may include an insertion device that is coupled to the body and that may be used to aid in insertion of the device, and a needle guard that is coupled to the body and that may be used to protect users from inadvertent needle sticks. In some embodiments of the present fluid delivery devices, a rigid cannula may be used instead of a needle guide and a soft cannula.
Some embodiments of the present systems (which may be characterized as fluid delivery systems) include one or more of the present fluid delivery devices that have been sterilized and enclosed in a package, with or without instructions for use contained within the package.
Some embodiments of the present methods (which may be characterized as fluid delivery methods) include installing one of the present fluid delivery devices to a user, and delivering fluid through the device and into the user.
The following drawings illustrate by way of example and not limitation. Identical reference numbers do not necessarily indicate an identical structure. Rather, the same reference number may be used to indicate a similar feature or a feature with similar functionality, as may non-identical reference numbers. Every feature of each embodiment is not always labeled in every figure in which that embodiment appears, in order to keep the figures clear. The figures are drawn to scale, meaning the sizes of the depicted elements are accurate relative to each other for at least one set of embodiments of the present fluid delivery devices.
The terms “comprise” (and any form of comprise, such as “comprises” and “comprising”), “have” (and any form of have, such as “has” and “having”), “contain” (and any form of contain, such as “contains” and “containing”), and “include” (and any form of include, such as “includes” and “including”) are open-ended linking verbs. As a result, a device, a system or a method that “comprises,” “has,” “contains,” or “includes” one or more recited elements or steps possesses those recited elements or steps, but is not limited to possessing only those elements or steps; it may possess elements or steps that are not recited. Likewise, an element of a device, system or method that “comprises,” “has,” “contains,” or “includes” one or more recited features possesses those features, but is not limited to possessing only those features; it may possess features that are not recited. Furthermore, a structure that is configured in a certain way must be configured in at least that way, but also may be configured in a way or ways that are not specified.
Thus, and by way of example, a fluid delivery device comprising a body having a first inlet, a first fluid delivery passageway extending from the first inlet, and a second fluid delivery passageway; a cannula having a portion that is coaxial with a portion of one of the first and second fluid delivery passageways; and a passageway closing structure oriented in a first position that substantially prevents fluid from flowing from the first inlet through the first fluid delivery passageway and out of the body, while allowing fluid to flow through the second fluid delivery passageway; the passageway closing structure being movable to a second position that substantially prevents fluid from flowing through the second fluid delivery passageway while allowing fluid to flow through the first fluid delivery passageway, is a fluid delivery device that possesses the recited body, cannula, and passageway closing structure, but is not limited to possessing only the recited elements (thus, other non-recited elements are not excluded). For example, the fluid delivery device also may include one or more septa.
Furthermore, the elements recited are not limited to possessing only the recited features. For example, the passageway closing structure may pivot about an axis that is centered within a portion of one of the fluid delivery passageways. As another example, an axis that is centered within or parallel to a portion of a passageway is one that is centered within or parallel to at least the portion, and may be centered within or parallel to the entire passageway. Similarly, a structure (e.g., a needle guide) “having” a portion positioned within a fluid delivery passageway has at least the portion positioned in the passageway, and may be positioned entirely within the passageway.
In any of the claims, the term “consisting of” or “consisting essentially of” may be substituted for any of the open-ended linking verbs recited above, in order to change the scope of a given claim from what it would otherwise be using the open-ended linking verb.
The terms “a” and “an” are defined as one or more than one unless this disclosure explicitly requires otherwise. The terms “substantially” is defined as at least close to (and includes) a given value or state (preferably within 10% of, more preferably within 1% of, and most preferably within 0.1% of).
The present fluid delivery devices may be used to deliver fluid to a living being for any of a variety of reasons. For example, some embodiments of the present fluid delivery devices may be used to deliver insulin to the subcutaneous tissue of a person with diabetes. However, embodiments of the present fluid delivery devices also may be used to deliver other fluids, such as saline, medication other than insulin, chemicals, enzymes, antigens, hormones, vitamins or the like, into subcutaneous tissue or other types of tissue, such as the epidermis, dermis, and different types of sub-dermal tissue such as muscle. The embodiments of the present fluid delivery devices shown in the figures are adapted for use with humans; however, those of ordinary skill in the art will, in light of this disclosure, understand that other embodiments may be adapted for use with animals.
The present fluid delivery devices may be characterized as ports, fluid delivery ports, injection ports, injection aides, infusion ports or infusion devices. The present fluid delivery systems may be characterized as injection systems or infusion systems.
Insertion device 70 comprising an insertion needle 72 connected to an insertion device hub 74. As shown in
Body 20 and insertion device 70 may be configured such that insertion device 70 cannot rotate with respect to body 20 when fully inserted in body 20. One manner of achieving this configuration comprises providing hub 74 with rotation-restricting protrusions 71, which extend in a downstream or downward direction from the main portion of insertion device hub 74, and by providing cap element 24 of body 20 with rotation-restricting recesses 77. When insertion device 70 is fully inserted in body 20, as shown in
Body 20 includes a fluid delivery passageway 25, which extends from entrance opening 21 (which also may be characterized as inlet port 21, or inlet 21) in cap element 24 through exit opening 23 in base element 22. Cap element 24 includes a portion 26 that tapers inwardly, or in a downstream direction, and extends from entrance opening 21 to a straight-walled portion 27 (“straight” meaning that, in this embodiment, the portion has no bend and a constant diameter), which extends to the bottom surface of cap element 24 and terminates at cap element exit opening 28. The portion of cap element 24 that overlaps an outer portion of septum 40 may be characterized as a sealing mechanism-retaining shoulder, or a septum retaining shoulder. Base element 22 includes a base element entrance opening 31 from which a straight-walled portion 32 extends. Straight-walled portion 32 ends at tapered wall portion 33, which extends into another straight-walled portion 34. Straight-walled portion 34 extends into a tapered portion 35 that ends at exit opening 23. Fluid delivery passageway 25 is characterized by all of these portions and openings.
In this embodiment, location 29 lies in a plane (not shown) that is substantially perpendicular to an axis (not shown) that is parallel to a portion of fluid delivery passageway 25. (The axis also is parallel to a portion of the cannula passageway of cannula 60.) The plane also may be characterized as being, in this embodiment, parallel to the bottom surface of body 20. The plane may be referred to as a device plane, and it is a plane in which the two body elements—cap element 24 and base element 22—may be assembled.
Cannula 60 of fluid delivery device 100 has a portion (specifically, an upper portion in the depicted embodiment) positioned within fluid delivery passageway 25. Cannula 60 has a portion that is substantially coaxial with a portion of fluid delivery passageway 25. More specifically, in the depicted embodiment, cannula 60 is coaxial with fluid delivery passageway 25. Needle guide 50 has a portion (specifically, all in the depicted embodiment) positioned within fluid delivery passageway 25 and also within cannula 60 (or the cannula passageway of cannula 60). Needle guide 50 has a portion that is substantially coaxial with a portion of fluid delivery passageway 25. More specifically, in the depicted embodiment, needle guide 50 is coaxial with fluid delivery passageway 25. Needle guide 50 also has a portion that is substantially coaxial with a portion of cannula 60. More specifically, in the depicted embodiment, needle guide 50 is coaxial with cannula 60 (or the cannula passageway).
This figure, like
As shown in
Accessible surface portion 42 has a perimeter, which is defined by cap element exit opening 28. The perimeter has a greatest width W42, which comprises the greatest distance between any two points along the perimeter that are connected by a straight line. In this embodiment, the perimeter is circular in shape, and greatest width W42 comprises the diameter of the circle. Other embodiments of the present fluid delivery devices may have cap element exit openings, and therefore accessible portions of the septa, that have different shapes. Bottom surface 44 of septum 40 has a perimeter that, in the depicted embodiment, is circular. The perimeter has a greatest width W44, which comprises the greatest distance between any two points along the perimeter that are connected by a straight line. In this embodiment, greatest width W44 comprises the diameter of the circle defined by bottom surface 44, although in other embodiments the bottom surface may be shaped differently. Bottom surface 44 may be more broadly characterized as a portion of the exterior surface of septum 40 (a “surface portion”) that is adjacent to open space 15 that is downstream of the surface portion and within fluid delivery passageway 25.
As
Cannula 60 has a smallest internal width Wc (see
Septum shapes other than the one shown, for example, in
Furthermore, some or all of a given septum (e.g., the portion of septum 40 that includes accessible surface portion 42) may be artificially-colored (e.g., by adding a coloring agent to the material that forms the septum). This may enhance the contrast between the septum and the remainder of the fluid delivery device.
Each of
In
In
In
The septa shown in each of
Generally,
When the fluid delivery device is made from two or more pieces or elements, there are many suitable configurations for those elements.
The cannulas shown in the figures described above are separate from the body of the depicted fluid delivery devices. In some other embodiments, the cannula may be integrally formed with the body. An example of such an embodiment is fluid delivery device 400, shown in
Multi-piece or multi-element bodies other than those shown in
Fluid delivery device 500 is similar in some respects to the previously-depicted embodiments. It includes a body 220, a septum 40, a needle guide 50 and a cannula 60. Body 220, however, comprises two elements 222 and 224 that assembly in a device plane that, in this embodiment, is parallel to fluid delivery passageway 225. Body 220 also includes needle guard holding recess 247 that is configured to accept a top portion of a needle guard such that the needle guard may be held to body through a friction fit, or any other suitable means of engagement. Elements 222 and 224 have substantially the same height. More specifically, height H222 and H224 (see
The features of body 220 are similar in function to those of body 20, and thus have been numbered as they are for body 20 except for a 200 added to the number. Thus, inlet port 221 is similar in shape and function and to inlet port 21. Some of the features of body 220 are labeled in
Some embodiments of the present fluid delivery devices may use a cannula having a sharp end, which may be a centerpoint end or a beveled end (as shown) and which in some embodiments may be characterized as having a “tipped” end. Such a cannula may be open at one end, as shown in
Cap element 324 may define an upper portion of the fluid delivery passageway 325. Specifically, cap element 324 includes entrance opening 321 (or inlet port 321, or inlet 321) of the device, a portion 326 that tapers inwardly, or in a downstream direction, and extends from entrance opening 321 to a straight-walled portion 327, which extends to the bottom surface of cap element 24 and terminates at cap element exit opening 328. Cap element 324 also includes cap element attachment protrusions 343 (four of them in this embodiment) that can be positioned in base element attachment recesses 341 of base element 322. The locations 329 at which the protrusions and recesses meet after attachment (through, e.g., ultrasonic welding) defines a device plane that is substantially perpendicular to an axis centered within a portion of fluid delivery passageway 325.
Intermediate element 301 includes multiple openings 303 sized to allow cap element attachment protrusions 343 to pass through them. As
Base element 322 may define a lower part of fluid delivery passageway 325. Base element 322 includes a base element entrance opening 331 from which a tapered wall portion 333 extends. Tapered wall portion 333, which may include an upper portion having a inward, or downstream, taper of constant angle and a lower portion that tapers, but not at a constant angle. Tapered wall portion 333 extends into straight-walled portion 334, which extends into another tapered portion 335 that terminates at exit opening, or exit port, 323. An inner portion 307 of base element 322 fits within the recess defined by the inner wall of outer portion 304 and the bottom of inner portion 302. Inner portion 307 includes inner central portion 349 and needle guard holding recess 347.
Needle guide 50 extends up to and contacts an outer surface (a portion of the bottom surface, in this embodiment) of inner portion 302 of intermediate element 301. In this embodiment, the portion of the intermediate element 301 acting as the septum for the fluid delivery passageway does not include any material that is positioned within needle guide 50 or cannula 60. However, in other embodiments, inner portion 302 may include a septum protrusion positioned to fit within a portion of the needle guide (and, more specifically, the needle guide passageway) and the cannula (and, more specifically, the cannula passageway). The embodiment of fluid delivery device 600 shown in
Fluid delivery device 600 is another embodiment of a fluid delivery device having an outer perimeter (outer perimeter 337) and a cannula positioned such that any portion of the cannula that is above a user's skin when the device is used is positioned within the outer perimeter of the device. In this embodiment, a portion (more specifically, a majority) of the outer surface of body 320 has a convex shape.
Multi-Inlet Fluid Delivery Devices
Some embodiments of the present fluid delivery devices comprise multiple inlets, a fluid delivery passageway extending from each inlet, and a septum for each passageway where the septa are not in contact with each other. One of the fluid delivery passageways may be oriented at a non-zero angle to another of the passageways. One fluid delivery passageway may extend into another. Some multi-inlet embodiments comprise only one outlet.
Fluid delivery device 700 includes a body 620 and an adhesive layer 630 attached to the body. As with all of the present fluid delivery devices, device 700 may also include an insertion device (not shown) and a needle guard 680. Body 620 includes rotation-restricting recesses 677, which function like the rotation-restricting recesses described above. The insertion device hub of any insertion device used with body 620 may be provided with complimentary rotation-restricting protrusions that function like those described above. Body 620 also includes a needle guard holding recess 647, which functions like the needle guard holding recess described above. In this embodiment, needle guard holding recess 647 is not a generally cylindrical recess—it extends around the base element of body 620 less than 360 degrees. Needle guard 680 has a notch 681 corresponding to the non-recessed portion of the base element, as shown in
Body 620 includes two inlet ports, 605 and 615. Inlet port 605 (also inlet 605 or entrance opening 605) is centered within the cap element of body 620. Inlet port 605 also is perpendicular to the normal direction that fluid delivery device 700 will be installed to a living being (that direction being substantially parallel to cannula 660, discussed below), and to an axis (not shown) centered within a portion of the fluid delivery passageway extending from it. Inlet 615 is not centered within the cap element of body 620. Inlet 615 is oriented at an angle between zero and ninety degrees to the axis centered within the central fluid delivery passageway and to the normal direction of insertion of the device.
Body 620 includes fluid delivery passageway 635 extending to exit opening 623 from inlet 605, and fluid delivery passageway 645 extending from inlet 615 into fluid delivery passageway 635 at a non-zero angle, such as an angle A (see
Fluid delivery device 700 includes another needle guide 655 that has a portion positioned within, and is coaxial with, fluid delivery passageway 635. Device 700 also includes a cannula 660 having a portion (in this embodiment, an upper portion) positioned within fluid delivery passageway 635. In this embodiment, fluid delivery passageway 635, needle guide 655 and cannula 660 are coaxial with each other. Device 700 also includes another septum 652, which is separate from septum 662, having a portion positioned within fluid delivery passageway 635, but no portion (in this embodiment) positioned within either needle guide 655 or cannula 660. Septum 652 is wedged between a portion of cap element 624 and a portion of base element 622 and helps to seal body cavity 619, as does septum 662. Both cannula 660 and needle guide 655 have a side opening (unnumbered) that allows fluid to enter fluid delivery passageway 635 from passageway 645. Body 620 is characterized by outer perimeter 637.
The topmost plane PTOP in which the top of device 700 lies is parallel to plane PES. The body has a height Hbody characterized by the distance between planes PTOP and PES taken along a line extending perpendicularly between both planes. Fluid delivery passageway 635 has a length L2 that comprises length L1, which extends between inlet 605 and the location at which the axis centered within fluid delivery passageway 645 meets the axis centered within fluid delivery passageway 635, and length L4, which extends from the end of L1 to exit opening 623 of body 620. The longest fluid delivery passageway within body 620 comprises a combination of fluid delivery passageways 645 and 635, and has a length of L3 (which extends from inlet 615 to the location defined by the downstream end of L1) plus L4.
Some embodiments of the multi-inlet fluid delivery devices may be configured for connection to an infusion pump, and may include a passageway closing structure that can be moved between positions. In one position, the passageway closing structure inhibits some fluid flow through one of the passageways while allowing it through another, and in another position the opposite effect may be achieved. The passageway closing structure may be biased to one of the positions.
Fluid delivery device 800 is similar in some respects to the embodiment of fluid delivery device 100 depicted, for example, in
Body 720 includes two inlet ports, 705 and 715. Inlet port 705 (also inlet 705 or entrance opening 705) is centered within the cap element of body 720. Inlet port 705 also is perpendicular to the normal direction that fluid delivery device 800 will be installed to a living being, and to an axis (not shown) centered within a portion of the fluid delivery passageway extending from it. Inlet 715 is not centered within the cap element of body 720. Inlet 715 is oriented at an angle of ninety degrees to the axis centered within the central fluid delivery passageway and to the normal direction of insertion of the device.
Body 720 also includes an inlet fitting 717 extending downstream from inlet 715. Inlet fitting 717 defines an outer portion of the laterally-oriented fluid delivery passageway of body 720, and may be adapted to be releasably coupled to an infusion pump connector fitting. For example, inlet fitting 717—which is depicted generically in
Fluid delivery device 800 includes needle guide 755 that has a portion positioned within, and is coaxial with, fluid delivery passageway 735. Device 800 also includes a cannula 760 having a portion (in this embodiment, an upper portion) positioned within and coaxial with fluid delivery passageway 735. In this embodiment, fluid delivery passageway 735, needle guide 755 and cannula 760 are coaxial with each other. Device 800 also includes another septum 752, which is separate from septum 762, having a portion positioned within fluid delivery passageway 735. Septum 752 is configured like septum 40 from the embodiment of fluid delivery device 100 shown, for example, in
Both cannula 760 and needle guide 755 have a side opening (unnumbered) that allows fluid to enter fluid delivery passageway 735 from passageway 745. Body 720 is characterized by outer perimeter 737.
Passageway closing structure 790 may have any suitable shape. For example, it may have an edge that is curved to match the configuration of the portion of the inner wall of needle guide 755 that it contacts or approaches in the first position. Furthermore, if passageway closing structure 790 is structured to contact needle guide 755 (opposite its coupling location to needle guide 755) in order to at least partially block fluid flow through fluid delivery passageway 735, the passageway closing structure may be coated with a material that helps to increase the friction between it and needle guide 755 in order to help it maintain its first position. Passageway closing structure 790 may be made from any suitable material. For example, passageway closing structure 790 may be made from the same material as needle guide 755 in some embodiments, and from a different material in other embodiments. Passageway closing structure may be biased to the first position shown in
Another multi-inlet embodiment that includes a passageway closing structure is depicted in
Passageway closing structure 791 is shown in perspective in
In the first position shown in
In the second position shown in
The present fluid delivery systems may include on or more of the present fluid delivery devices that are sterilized (e.g., with ethylene oxide or gamma radiation) and sealed in a package, which may take the form of a pouch, tray, box (such as a box containing multiple trays), tube, or the like. The package may include instructions for use on the outside of the package or on material (e.g., a folded piece of paper) placed in the package. In some embodiments of systems that include a package containing multiple trays for resale, one set of instructions for use may be placed in the package. The systems also may include a vial or vials of fluid to be delivered to the user (such as insulin).
The materials from which the elements of the present fluid delivery devices may be made should be biocompatible. The septa that may be used with some embodiments of the present fluid delivery devices may be characterized as self-sealing septa, or resealing septa, and may be made from a resilient material. One example of a suitable material for such septa is silicone elastomer, which may be described as an elastomeric material, although other materials may be used. If the injection structure chosen to inject fluid into a given embodiment of the present fluid delivery devices is an injection needle, the injection needle used should be sized such that the septum will reseal when the needle is withdrawn. For example, the needle size should be chosen in light of the septum material and the radial pressure the needle will exert on the septum material it contacts such that the needle does not leave a septum opening when withdrawn that is large enough for fluid to leak upstream through it.
The bodies of the present fluid delivery devices (e.g., both the caps and bases of the two-element bodies) may be made from many different materials, such as any suitable medical grade plastic. The insertion hubs (or handles) (e.g., insertion hub 74) of the present fluid delivery devices that include them also may be made, for example, from any suitable medical grade plastic. The insertion structures (e.g., insertion needle 72) of the present fluid delivery devices that include them may be made from any suitable material, such as stainless steel or a suitably rigid polymer. The needle guides (e.g., needle guide 50) of the present fluid delivery devices that include them may be made from any suitable material, such as stainless steel, although other materials may be used. The embodiments of the present needle guides that are made from metal, such as an alloy, may be characterized as metal needle guides. The soft cannulas (e.g., cannula 60) of the present fluid delivery devices that include them may be made from many different materials, such as any suitable medical grade plastic. Those that are not made from metal may be characterized as non-rigid cannulas or non-metal cannulas.
The needle guards (e.g., needle guard 80) of the present fluid delivery devices that include them may be made from many different materials, such as any suitable medical grade plastic. The adhesive layers or pads (e.g., adhesive layer 30) of the present fluid delivery devices that include them may be made from any suitable material, and any adhesive that is used may include an anti-bacterial and/or healing promotion substance (such as dexamethasone, or the like) that reduces the risk of infection and speeds the healing process once the fluid delivery device is removed from the user. The rigid cannulas (e.g., cannula 260) of the present fluid delivery devices that include them may be made from any suitable material—such as stainless steel, any suitable alloy or any suitably rigid polymer. Versions of the present rigid cannulas that are made from metal may (in such embodiments) be characterized as metal cannulas.
If a medical grade plastic is used for one of the elements discussed above, the material chosen may, be translucent, transparent, semi-transparent, or opaque in different embodiments.
Embodiments of the present fluid delivery devices that use a soft cannula may be inserted using any well-known and appropriately configured insertion device, such as the insertion devices shown in
As an alternative to the use of insertion devices with needles for inserting embodiments of the present fluid delivery devices that have a non-rigid cannula, an outer surface of the exposed portion of the cannula may be coated with a fluid soluble coating that provides a sharp tip, or point, at the end of the cannula, but that dissolves in the bodily fluids of the user after insertion. Such a coating is described in paragraphs 0035 to 0045 of U.S. Patent Application Pub. No. 2002/0072720, which paragraphs are incorporated by reference.
Different injection devices may be used to facilitate the delivery of fluid to, for example, the subcutaneous tissue of a user. For example, a standard syringe and syringe needle may be used. The syringe needle may be sharp and open at its end, sharp and open somewhere along its shaft other than at its end, blunt and open at its end, or blunt and open somewhere along its shaft other than at its end. Other suitable injection devices include pen-like devices having some sort of needle that is generally concealed. Injection of fluid into a patient using one of these injection devices may be characterized as delivering fluid to a user from a non-pump source, or delivering fluid to a user from a source that is not connected to a pump. In other embodiments of the present devices, systems and methods, a pump may be used in the fluid delivery process. For example, this is true of the fluid delivery devices that include an inlet fitting such as inlet fitting 717.
While the target tissue of a patient may be pinched and/or pulled outwardly from the body slightly to isolate it, insertion of one of the present fluid delivery devices into the tissue of a user still may, in some embodiments, be characterized as being at a substantially perpendicular angle to a target skin location of a user/living being because the rigid cannula or non-rigid cannula and insertion structure will enter the user's tissue at an angle that is substantially perpendicular to the plane in which the target tissue lies.
Some embodiments of the present methods include the use of the insertion and/or injection techniques described above.
The present fluid delivery devices, systems and methods are not intended to be limited to the particular forms disclosed. Rather, they include all modifications, equivalents, and alternatives falling within the scope of the claims. For example, the cap elements of the multi-element embodiments that include them can have configurations other than those depicted in the figures. Such cap elements may have an inlet that is not circular (e.g., the inlet may be rectangular, hexagonal, or octagonal), and the wall of the portion of the cap element that forms the upper portion of a given fluid delivery passageway may be straight-walled, may have a taper of constant angle, or may have a taper of non-constant angle.
As another example, multiple cannulas may extend from and be coupled to a body of one of the present fluid delivery devices such that the delivery of medication may be spread to different areas of a user's tissue. For example, a single inlet may be in fluid communication with multiple cannulas positioned to delivery fluid to a target tissue location; alternatively, a body may have multiple inlets, each of which is in fluid communication with a cannula positioned to deliver fluid to a target tissue location.
As another example, in some embodiments of the present fluid delivery systems, the package containing one or more of the present fluid delivery devices also may include one or more capsules, or vials, containing a prescribed amount of fluid. The package also may include a pump and associated tubing for coupling to a fitting such an inlet fitting 717.
As another example, some embodiments of the present fluid delivery devices that include a fluid delivery passageway having a portion oriented at an angle that is not parallel to the normal direction of insertion of the device may have only one inlet (although two inlets are illustrated in
As another example, an upper portion of a given fluid delivery passageway (including the inlet) may be set at an angle other than parallel to an intended direction of insertion for the device. Similarly, any portion of the cannula that is exposed when not inserted into a user (no such portions are shown in the figures, but may exist) may be set at a non-parallel angle to an intended direction of insertion for the device.
As another example, the needle guides shown in the figures are configured such that at least some open space exists below the bottommost portion of the septum positioned within the needle guide and above the beginning of the straight-walled portion of the needle guide. In other embodiments, the bottommost portion of the septum positioned within the needle guide may extend even further downstream such that there is less such open space than what is shown in the figures down to no such open space. In some embodiments of the present fluid delivery devices, one may want to put the length (or thickness) of the septum in compression to cause the septum to exert a radial force on the needle guide that tends to restrict upstream and downstream movement of the septum relative to the needle guide. Having at least some open space beneath the bottommost portion of the septum and the uppermost portion of the straight-walled portion of the needle guide may facilitate such compression.
The claims are not to be interpreted as including means-plus- or step-plus-function limitations, unless such a limitation is explicitly recited in a given claim using the phrase(s) “means for” or “step for,” respectively.
This is a division of U.S. application Ser. No. 13/557,026, now U.S. Pat. No. 9,039,660, filed Jul. 24, 2012, which is a continuation of U.S. application Ser. No. 11/592,719, now U.S. Pat. No. 8,226,614, filed Nov. 3, 2006, which claims priority to U.S. Provisional Patent Application Ser. No. 60/733,311 filed Nov. 3, 2006, all of which are incorporated by reference without disclaimer.
Number | Name | Date | Kind |
---|---|---|---|
3547119 | Hall et al. | Dec 1970 | A |
3620209 | Kravitz | Nov 1971 | A |
4311137 | Gerard | Jan 1982 | A |
4315513 | Nawash et al. | Feb 1982 | A |
4430081 | Timmermans | Feb 1984 | A |
4525164 | Loeb et al. | Jun 1985 | A |
4531937 | Yates | Jul 1985 | A |
4534758 | Akers et al. | Aug 1985 | A |
4568335 | Updike et al. | Feb 1986 | A |
4578063 | Inman et al. | Mar 1986 | A |
4675006 | Hrushesky | Jun 1987 | A |
4755173 | Konopka et al. | Jul 1988 | A |
4772261 | Von Hoff et al. | Sep 1988 | A |
4817631 | Schnepp-Pesch et al. | Apr 1989 | A |
4874377 | Newgard et al. | Oct 1989 | A |
4904241 | Bark | Feb 1990 | A |
4966588 | Rayman et al. | Oct 1990 | A |
5080654 | Picha et al. | Jan 1992 | A |
5092849 | Sampson | Mar 1992 | A |
5108377 | Cone et al. | Apr 1992 | A |
5122114 | Miller et al. | Jun 1992 | A |
5176653 | Metals | Jan 1993 | A |
5176662 | Bartholomew et al. | Jan 1993 | A |
5257980 | Van Antwerp et al. | Nov 1993 | A |
5306243 | Bonaldo | Apr 1994 | A |
5332398 | Miller et al. | Jul 1994 | A |
5342316 | Wallace | Aug 1994 | A |
5370625 | Shickman | Dec 1994 | A |
5409466 | Watson et al. | Apr 1995 | A |
5522803 | Teissen-Simony | Jun 1996 | A |
5545143 | Fischell | Aug 1996 | A |
5545152 | Fudnerburk et al. | Aug 1996 | A |
5569206 | Gorman et al. | Oct 1996 | A |
5584813 | Livingston et al. | Dec 1996 | A |
5607407 | Tolkoff et al. | Mar 1997 | A |
5618295 | Min | Apr 1997 | A |
5647851 | Pokras | Jul 1997 | A |
5718682 | Tucker | Feb 1998 | A |
5727770 | Dennis | Mar 1998 | A |
5749861 | Guala et al. | May 1998 | A |
5797879 | DeCampli | Aug 1998 | A |
5839895 | Fisburne | Nov 1998 | A |
5848989 | Villani | Dec 1998 | A |
5851197 | Marano et al. | Dec 1998 | A |
5871500 | Jepson et al. | Feb 1999 | A |
5873844 | Campero et al. | Feb 1999 | A |
5925017 | Kriesel et al. | Jul 1999 | A |
5951521 | Mastrototaro et al. | Sep 1999 | A |
5954684 | Flower et al. | Sep 1999 | A |
5954687 | Baudino | Sep 1999 | A |
5968011 | Larsen et al. | Oct 1999 | A |
5980506 | Mathiasen | Nov 1999 | A |
5989224 | Exline et al. | Nov 1999 | A |
6017328 | Fischell et al. | Jan 2000 | A |
6056718 | Funderburk et al. | May 2000 | A |
6068613 | Kriesel et al. | May 2000 | A |
6074371 | Fischell | Jun 2000 | A |
6086575 | Mejslov | Jul 2000 | A |
6093172 | Funderburk et al. | Jul 2000 | A |
6110154 | Shimomura et al. | Aug 2000 | A |
6123690 | Mejslov | Sep 2000 | A |
6176235 | Benarrouch et al. | Jan 2001 | B1 |
6231531 | Lum et al. | May 2001 | B1 |
6254586 | Mann et al. | Jul 2001 | B1 |
6293925 | Safabash et al. | Sep 2001 | B1 |
6302866 | Marggi | Oct 2001 | B1 |
6344033 | Jepson et al. | Feb 2002 | B1 |
6355021 | Nielsen et al. | Mar 2002 | B1 |
6387098 | Cole et al. | May 2002 | B1 |
6413244 | Bestetti et al. | Jul 2002 | B1 |
6461329 | Van Antwerp et al. | Oct 2002 | B1 |
6488663 | Steg | Dec 2002 | B1 |
6520938 | Funderburk et al. | Feb 2003 | B1 |
6572586 | Wojcik | Jun 2003 | B1 |
6579267 | Lynch et al. | Jun 2003 | B2 |
6585695 | Adair et al. | Jul 2003 | B1 |
6602229 | Coss | Aug 2003 | B2 |
6629949 | Douglas | Oct 2003 | B1 |
6641566 | Douglas et al. | Nov 2003 | B2 |
6659982 | Douglas et al. | Dec 2003 | B2 |
6673440 | Douglas et al. | Jan 2004 | B2 |
6685674 | Douglas et al. | Feb 2004 | B2 |
6699218 | Flaherty et al. | Mar 2004 | B2 |
6702761 | Damadian et al. | Mar 2004 | B1 |
6736797 | Larsen et al. | May 2004 | B1 |
6749587 | Flaherty | Jun 2004 | B2 |
6749589 | Douglas et al. | Jun 2004 | B1 |
6805693 | Gray et al. | Oct 2004 | B2 |
6840922 | Nielsen et al. | Jan 2005 | B2 |
6908459 | Harding et al. | Jun 2005 | B2 |
6960192 | Flaherty et al. | Nov 2005 | B1 |
6964649 | Goll | Nov 2005 | B2 |
7008383 | Damadian et al. | Mar 2006 | B1 |
7022108 | Marano-Ford et al. | Apr 2006 | B2 |
7029455 | Flaherty | Apr 2006 | B2 |
7033339 | Lynn | Apr 2006 | B1 |
7083597 | Lynch et al. | Aug 2006 | B2 |
7303543 | Mauel et al. | Dec 2007 | B1 |
7309326 | Fangrow, Jr. | Dec 2007 | B2 |
7338465 | Patton | Mar 2008 | B2 |
7494481 | Moberg et al. | Feb 2009 | B2 |
7520867 | Bowman et al. | Apr 2009 | B2 |
7524300 | Patton | Apr 2009 | B2 |
7569034 | Lynch et al. | Aug 2009 | B2 |
7704228 | Patton | Apr 2010 | B2 |
7713258 | Adams et al. | May 2010 | B2 |
7731680 | Patton | Jun 2010 | B2 |
7892216 | Fangrow, Jr. | Feb 2011 | B2 |
7931615 | Fangrow, Jr. | Apr 2011 | B2 |
7935090 | Patton | May 2011 | B2 |
8216208 | Patton | Jul 2012 | B2 |
8221361 | Patton | Jul 2012 | B2 |
8221362 | Patton | Jul 2012 | B2 |
8221386 | Patton | Jul 2012 | B2 |
8226614 | Turner et al. | Jul 2012 | B2 |
8262627 | Patton | Sep 2012 | B2 |
8366683 | Patton | Feb 2013 | B2 |
8551047 | Burns et al. | Oct 2013 | B2 |
8777925 | Patton | Jul 2014 | B2 |
9486575 | Patton | Nov 2016 | B2 |
20010053887 | Douglas et al. | Dec 2001 | A1 |
20010053889 | Marggi | Dec 2001 | A1 |
20010056064 | Aoki | Dec 2001 | A1 |
20020045867 | Nielsen et al. | Apr 2002 | A1 |
20020065484 | Douglas et al. | May 2002 | A1 |
20020072720 | Hague et al. | Jun 2002 | A1 |
20020072733 | Flaherty | Jun 2002 | A1 |
20020107476 | Maim et al. | Aug 2002 | A1 |
20020120231 | Douglas et al. | Aug 2002 | A1 |
20020123719 | Lavi et al. | Sep 2002 | A1 |
20020123724 | Douglas et al. | Sep 2002 | A1 |
20020123740 | Flaherty et al. | Sep 2002 | A1 |
20020128600 | Nissels | Sep 2002 | A1 |
20020151855 | Douglas et al. | Oct 2002 | A1 |
20020161332 | Ramey | Oct 2002 | A1 |
20020173769 | Gray | Nov 2002 | A1 |
20030023203 | Lavi et al. | Jan 2003 | A1 |
20030073952 | Flaherty et al. | Apr 2003 | A1 |
20030088238 | Poulsen et al. | May 2003 | A1 |
20030097092 | Flaherty | May 2003 | A1 |
20030100885 | Pettis et al. | May 2003 | A1 |
20030114751 | Pedain et al. | Jun 2003 | A1 |
20030176852 | Lynch et al. | Sep 2003 | A1 |
20030199823 | Bobroff et al. | Oct 2003 | A1 |
20030212364 | Mann et al. | Nov 2003 | A1 |
20030213723 | Lombardi | Nov 2003 | A1 |
20030216686 | Lynch et al. | Nov 2003 | A1 |
20040001809 | Brisken et al. | Jan 2004 | A1 |
20040002682 | Kovelman et al. | Jan 2004 | A1 |
20040006316 | Patton | Jan 2004 | A1 |
20040015134 | Lavi et al. | Jan 2004 | A1 |
20040030285 | Lavi et al. | Feb 2004 | A1 |
20040073160 | Pinkerton | Apr 2004 | A1 |
20040143216 | Douglas et al. | Jul 2004 | A1 |
20040143241 | Douglas et al. | Jul 2004 | A1 |
20040204687 | Mogensen et al. | Oct 2004 | A1 |
20040204690 | Yashiro et al. | Oct 2004 | A1 |
20040204691 | Yashiro et al. | Oct 2004 | A1 |
20040260235 | Douglas | Dec 2004 | A1 |
20040267238 | Haarala et al. | Dec 2004 | A1 |
20050092387 | Schorn et al. | May 2005 | A1 |
20050101910 | Bowman et al. | May 2005 | A1 |
20050101933 | Marrs et al. | May 2005 | A1 |
20050104473 | Yoshida | May 2005 | A1 |
20050107743 | Fangrow | May 2005 | A1 |
20050113761 | Faust et al. | May 2005 | A1 |
20050240154 | Mogensen et al. | Oct 2005 | A1 |
20060015076 | Heinzerling et al. | Jan 2006 | A1 |
20060030815 | Csincsura et al. | Feb 2006 | A1 |
20060129090 | Moberg et al. | Jun 2006 | A1 |
20060173386 | Lindquist | Aug 2006 | A1 |
20060217659 | Patton | Sep 2006 | A1 |
20060264818 | Patton | Nov 2006 | A1 |
20060264900 | Patton | Nov 2006 | A1 |
20060264901 | Patton | Nov 2006 | A1 |
20070049874 | Patton | Mar 2007 | A1 |
20070049875 | Patton | Mar 2007 | A1 |
20070049876 | Patton | Mar 2007 | A1 |
20070049877 | Patton | Mar 2007 | A1 |
20070088385 | Perry | Apr 2007 | A1 |
20070093756 | Patton | Apr 2007 | A1 |
20070093757 | Patton | Apr 2007 | A1 |
20070219510 | Zinn et al. | Sep 2007 | A1 |
20080021375 | Burns | Jan 2008 | A1 |
20080045891 | Maule et al. | Feb 2008 | A1 |
20080051714 | Moberg et al. | Feb 2008 | A1 |
20090163878 | Moberg et al. | Jun 2009 | A1 |
Number | Date | Country |
---|---|---|
1027540 | Oct 1975 | CA |
2189466 | Feb 1995 | CN |
2538364 | Mar 2003 | CN |
1558782 | Dec 2004 | CN |
1991-12459 | Sep 2000 | DE |
1991-12459 | Feb 2001 | DE |
0239244 | Sep 1987 | EP |
1 205 211 | May 2002 | EP |
1566193 | Aug 2005 | EP |
575559 | Aug 1924 | FR |
2607012 | May 1988 | FR |
1482052 | Aug 1977 | GB |
59-118152 | Jul 1984 | JP |
03-126438 | May 1991 | JP |
WO 8701041 | Feb 1987 | WO |
WO 8803816 | Jun 1988 | WO |
WO 9220400 | Nov 1992 | WO |
WO 2002040083 | May 2002 | WO |
WO 2005049117 | Jun 2005 | WO |
WO 2006097111 | Sep 2006 | WO |
WO 2007040853 | Apr 2007 | WO |
WO 2007056309 | May 2007 | WO |
Entry |
---|
Examination Report issued in Indian Patent Application No. 2424/DELNP/2008, dated Dec. 21, 2015. |
Examination Report issued in Indian Patent Application No. 4282/DELNP/2008, dated Jan. 25, 2016. |
Extended European Search Report issued in European Patent Application No. 06789895.7, dated Aug. 3, 2016. |
Minutes of Oral Proceeds issued in European Patent Application No. 03739327.9, dated Apr. 4, 2013. |
Notice of Allowance issued in U.S. Appl. No. 11/466,349, dated Jun. 6, 2013. |
Notice of Allowance issued in U.S. Appl. No. 14/332,185, dated Jul. 7, 2016. |
Office Action issued in Australian Patent Application No. 2006311708, dated Sep. 22, 2011. |
Office Action issued in Australian Patent Application No. 2013206380, dated Nov. 24, 2014. |
Office Action Issued in Australian Patent Application No. 2015258342, dated Aug. 22, 2016. |
Office Action issued in Australian Patent Application No. 2015258342, dated May 10, 2017. |
Office Action issued in Australian Patent Application No. 2015258342, dated Jul. 3, 2017. |
Office Action issued in Chinese Patent Application No. 200680038075.2, dated Feb. 29, 2012. |
Office Action issued in Chinese Patent Application No. 200680038075.2, dated Mar. 4, 2013. |
Office Action issued in Chinese Patent Application No. 200680038075.2, dated Jan. 14, 2014. |
Office Action issued in European Patent Application No. 03739327.9, dated Apr. 9, 2012. |
Office Action issued in European Patent Application No. 03739327.9, dated Sep. 24, 2014. |
Office Action issued in European Patent Application No. 03739327.9, dated Sep. 21, 2015. |
Office Action issued in U.S. Appl. No. 11/466,349, dated Jul. 21, 2011. |
Office Action issued in U.S. Appl. No. 11/466,349, dated Mar. 19, 2012. |
Office Action Issued in U.S. Appl. No. 14/332,185, dated Dec. 17, 2014. |
Office Action issued in U.S. Appl. No. 14/332,185, dated Apr. 8, 2015. |
Office Action issued in U.S. Appl. No. 14/332,185, dated Aug. 20, 2015. |
Office Action issued in U.S. Appl. No. 14/332,185, dated May 2, 2016. |
Record of Examiner Interview issued in European Patent Application No. 03739327.9, dated Apr. 3, 2017. |
Response to Office Action issued in U.S. Appl. No. 11/466,349, dated Dec. 21, 2011. |
Response to Office Action issued in U.S. Appl. No. 11/466,349, dated Sep. 19, 2012. |
Response to Office Action Issued in U.S. Appl. No. 14/332,185, dated Mar. 17, 2015. |
Response to Office Action issued in U.S. Appl. No. 14/332,185, dated Aug. 10, 2015. |
Response to Office Action issued in U.S. Appl. No. 14/332,185, dated Jan. 8, 2016. |
Response to Office Action issued in U.S. Appl. No. 14/332,185, dated Jun. 16, 2016. |
Summons to Attend Oral Proceedings issued in European Patent Application No. 03739327.9, dated Aug. 9, 2016 |
Supplementary Search Report issued in European Patent Application No. 03739327.9, dated Jul. 5, 2012. |
“Insuflon” retrieved on Nov. 12, 2004 from http://www.poara.com/eng/insuflon/insuflon.htm. |
Altman et al., “The Revised Consort Statement for Reporting Randomized Trials: Explanation and Elaboration,” Annals Internal Medicine, 134:663-694, 2001. |
American Diabetes Association “Standards of medical care for patients with diabetes mellitus.” Diabetes Care, 25:213-29, 2002. |
Anderson et al., “The use of an indwelling Teflon catheter for subcutaneous heparin administration during pregnancy. A randomized crossover study.” Arch. Intern. Med., 153:841-4, 1993. |
Chinese Search Report issued in Chinese Application No. 2006800475377, dated Aug. 27, 2012. |
Dyer et al., “Insuflon Versus Subcutaneous Injection for Cytokine Administration in Children for Cytokine Administration in Children and Adolescents: A Randomized Crossover Study,” J. Pediatric Oncology Nursing, 21:79-86, 2004. |
English Translation of Office Action issued in Chinese Application No. 038158213, dated Jul. 6, 2007. |
English Translation of Office Action issued in Chinese Application No. 038158213, dated Feb. 20, 2009. |
English Translation of Office Action issued in Chinese Patent App. No. 03815821.3, dated Jun. 26, 2009. |
English Translation of Office Action issued in Japanese Application No. 2004-519654, dated Apr. 28, 2008. |
English Translation of Office Action issued in Japanese Application No. 2004-519654, dated Nov. 25, 2008. |
FDA, Section 510(k) Notification for Viggo Insuflon, Aug. 24 1998, Silver Spring, Maryland. |
File History of U.S. Appl. No. 09/110,360, filed Jul. 6, 1998. |
Graham et al.;“Control of Important Clinical Parameters for Patients with Type 2 Diabetes Mellitus,” Diabetes,. 51:A-274, 2002 (Abstract No. 1112-P). |
Hanas et al.; “Experience of Pain from Insulin Injections Using Syringes Pens and Indwelling Catheters.” Department of Pediatrics, Uddevalla Hospital, Uddevalla Sweden. Abstract. 1989. |
Hanas et al.: “Metabolic control is not altered when using indwelling catheters for insulin injections.”Diabetes Care, 17:716-8, 1994. |
Hanas et al.; “Side effects and indwelling times of subcutaneous catheters for insulin injections: a new device for injecting insulin with a minimum of pain in the treatment of insulin-dependent diabetes mellitus.” Diabetes Res. Clin. Pract., 10:73-83, 1990. |
Hanas et al.; “Unchanged insulin absorption after 4 days' use of subcutaneous indwelling catheters for insulin injections.” Diabetes Care, 20:487-90, 1997. |
Hanas et al., “X-ray appearance of the indwelling catheter when using insuflon for insulin injections.” Department of Pediatrics Uddevalla Hospital, Uddevalla, Sweden. Abstracts of the 17th Annual Meeting of ISGD, Hormone Research 35:58, 1991. |
Hanas, “Reducing injection pain in children and adolescents with diabetes: a review of indwelling catheters,” Pediatric Diabetes, 5:102, 2004. |
Heine, “A Randomized trial of continuous subcutaneous insulin infusion and intensive injection therapy in type 1 diabetes for patients with long-standing poor glycemic control,” Diabetes Care, Nov. 1, 2002. |
Henry et al., “Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-mo outpatient trial.” Diabetes Care, 16:21-31, 1993. |
Hunt et al. “NIDDM patients' fears and hopes about insulin therapy. The basis of patient reluctance.” Diabetes Care, 20:292-8, 1997. |
International Search Report and Written Opinion issued in PCT/US06/32609, dated Feb. 27, 2007. |
International Search Report and Written Opinion issued in PCT/US06/43231, dated May 14, 2007. |
Kaar et al., “Insulin Administration via a Subcutaneous Catheter: Effects on absorption,” Diabetes Care, 16:1412-1413, 1993. |
Knip et al., “No evidence of an accelerated absorption of exogenous insulin after using a subcutaneous catheter for 5 days in children with IDDM” Diabetes Care, Jun. 17:627, 1994. |
Koro et al., “Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report,” Diabetes Care, 27:17-20, 2004. |
Lamacraft et al., “Subcutaneous cannulae for morphine boluses in children: assessment of a technique,” J. Pain Symptom Manage., 13:43-9, 1997. |
Liu et al., “Insulin absorption is faster when keeping the infusion site in use for three days during continuous subcutaneous insulin infusion.” Diabetes Res. Clin. Pract., 12:19-24, 1991. |
Long and Hughes,. “Indwelling cannula for insulin administration in diabetes mellitus.” Arch. Dis. Child, 66:348-9, 1991. |
McGrath et al., “A new analogue scale for assessing children's pain: an initial validation study,” Pain, Mar; 64:435-43, 1996. |
Notice of Allowance, issued in U.S. Appl. No. 11/483,218, dated Oct. 7, 2008. |
Notice of Allowance, issued in U.S. Appl. No. 11/483,218, dated Feb. 10, 2009. |
Office Action in Canadian App. No. 2,490,549, dated Feb. 23, 2010. |
Office Action in Canadian Patent Application No. 2,490,549, dated Dec. 20, 2010. |
Office Action in U.S. Appl. No. 11/372,681, dated May 6, 2010. |
Office Action in U.S. Appl. No. 11/483,219, dated Dec. 16, 2010. |
Office Action in U.S. Appl. No. 10/188,591, dated Dec. 15, 2005. |
Office Action in U.S. Appl. No. 10/188,591, dated Dec. 15, 2006. |
Office Action in U.S. Appl. No. 10/188,591, dated Feb. 27, 2006. |
Office Action in U.S. Appl. No. 10/188,591, dated Jun. 7, 2006. |
Office Action in U.S. Appl. No. 10/188,591, dated May 30, 2007. |
Office Action in U.S. Appl. No. 10/188,591, dated Sep. 20, 2006. |
Office Action in U.S. Appl. No. 11/372,681, dated Aug. 25, 2006. |
Office Action in U.S. Appl. No. 11/372,681, dated Aug. 24, 2007. |
Office Action in U.S. Appl. No. 11/372,681, dated Aug. 6, 2009. |
Office Action in U.S. Appl. No. 11/372,681, dated Dec. 27, 2007. |
Office Action in U.S. Appl. No. 11/372,681, dated Feb. 23, 2007. |
Office Action in U.S. Appl. No. 11/372,681, dated Feb. 20, 2009. |
Office Action in U.S. Appl. No. 11/372,681, dated May 1, 2008. |
Office Action in U.S. Appl. No. 11/372,681, dated Nov. 20, 2009. |
Office Action in U.S. Appl. No. 11/372,681, dated Sep. 12, 2008. |
Office Action in U.S. Appl. No. 11/466,349 dated Jun. 12, 2009. |
Office Action in U.S. Appl. No. 11/466,349, dated Nov. 6, 2009. |
Office Action in U.S. Appl. No. 11/466,349, dated May 4, 2011. |
Office Action in U.S. Appl. No. 11/482,265, dated Aug. 25, 2006. |
Office Action in U.S. Appl. No. 11/482,265, dated Apr. 3, 2008. |
Office Action in U.S. Appl. No. 11/482,265, dated Dec. 11, 2007. |
Office Action in U.S. Appl. No. 11/482,265, dated Dec. 16, 2010. |
Office Action in U.S. Appl. No. 11/482,265, dated Jan. 12, 2009. |
Office Action in U.S. Appl. No. 11/482,265, dated Jun. 10, 2010. |
Office Action in U.S. Appl. No. 11/482,265, dated May 30, 2007. |
Office Action in U.S. Appl. No. 11/482,265, dated Nov. 30, 2006. |
Office Action in U.S. Appl. No. 11/482,265, dated May 29, 2009. |
Office Action in U.S. Appl. No. 11/482,265, dated Nov. 17, 2009. |
Office Action in U.S. Appl. No. 11/483,219, dated Apr. 3, 2008. |
Office Action in U.S. Appl. No. 11/483,219, dated Aug. 11, 2006. |
Office Action in U.S. Appl. No. 11/483,219, dated Dec. 11, 2007. |
Office Action in U.S. Appl. No. 11/483,219, dated Jan. 12, 2009. |
Office Action in U.S. Appl. No. 11/483,219, dated Jun. 9, 2010. |
Office Action in U.S. Appl. No. 11/483,219, dated May 30, 2007. |
Office Action in U.S. Appl. No. 11/483,219, dated May 29, 2009. |
Office Action in U.S. Appl. No. 11/483,219, dated Nov. 30, 2006. |
Office Action in U.S. Appl. No. 11/483,219, dated Nov. 17, 2009. |
Office Action in U.S. Appl. No. 11/532,747, dated Dec. 27, 2007. |
Office Action in U.S. Appl. No. 11/532,747, dated Jun. 30, 2008. |
Office Action in U.S. Appl. No. 11/532,747, dated Mar. 18, 2009. |
Office Action in U.S. Appl. No. 11/532,747, dated Mar. 31, 2010. |
Office Action in U.S. Appl. No. 11/532,747, dated Nov. 17, 2011. |
Office Action in U.S. Appl. No. 11/532,747, dated Oct. 8, 2008. |
Office Action in U.S. Appl. No. 11/532,747, dated Oct. 21, 2009. |
Office Action in U.S. Appl. No. 11/532,772, dated Apr. 28, 2010. |
Office Action in U.S. Appl. No. 11/532,772, dated Jan. 12, 2011. |
Office Action in U.S. Appl. No. 11/532,772, dated Jun. 2, 2009. |
Office Action in U.S. Appl. No. 11/532,772, dated Nov. 12, 2008. |
Office Action in U.S. Appl. No. 11/532,772, dated Oct. 23, 2009. |
Office Action in U.S. Appl. No. 11/532,824, dated Apr. 1, 2009. |
Office Action in U.S. Appl. No. 11/532,824, dated May 12, 2010. |
Office Action in U.S. Appl. No. 11/532,824, dated Oct. 22, 2009. |
Office Action in U.S. Appl. No. 11/532,836, dated Aug. 6, 2009. |
Office Action in U.S. Appl. No. 11/532,836, dated Feb. 20, 2009. |
Office Action in U.S. Appl. No. 11/532,836, dated Jan. 29, 2008. |
Office Action in U.S. Appl. No. 11/532,836, dated Jan. 11, 2011. |
Office Action in U.S. Appl. No. 11/532,836, dated Jun. 27, 2008. |
Office Action in U.S. Appl. No. 11/532,836, dated May 20, 2010. |
Office Action in U.S. Appl. No. 11/532,836, dated Nov. 19, 2009. |
Office Action in U.S. Appl. No. 11/532,836, dated Sep. 17, 2008. |
Office Action in U.S. Appl. No. 11/532,845, dated Apr. 9, 2009. |
Office Action in U.S. Appl. No. 11/532,845, dated Oct. 30, 2009. |
Office Action in U.S. Appl. No. 11/532,858, dated Apr. 9, 2009. |
Office Action in U.S. Appl. No. 11/532,858, dated Oct. 30, 2009. |
Office Action in U.S. Appl. No. 11/592,719, dated Dec. 10, 2010. |
Office Action in U.S. Appl. No. 11/592,719, dated Jun. 1, 2011. |
Office Action in U.S. Appl. No. 11/592,719, dated Nov. 18, 2010. |
Office Action in U.S. Appl. No. 11/592,719, dated Oct. 18, 2010. |
Office Action in U.S. Appl. No. 12/042,206, dated Mar. 23, 2011. |
Office Action in U.S. Appl. No. 12/042,206, dated Sep. 20, 2010. |
Office Action in U.S. Appl. No. 12/042,212, dated Jan. 18, 2011. |
Office Action in U.S. Appl. No. 11/372,681, dated Dec. 16, 2010. |
Office Action in U.S. Appl. No. 11/483,218, dated Apr. 8, 2008. |
Office Action in U.S. Appl. No. 11/483,218, dated Aug. 25, 2006. |
Office Action in U.S. Appl. No. 11/483,218, dated Jul. 27, 2007. |
Office Action in U.S. Appl. No. 11/483,218, dated Mar. 26, 2007. |
Office Action in U.S. Appl. No. 11/483,218, dated Nov. 30, 2006. |
Office Action issued in Chinese Application No. 2006800475377, dated Oct. 29, 2010. |
Office Action issued in Chinese Application No. 2006800475377, dated Jul. 13, 2011. |
Office Action issued in Chinese Patent Application No. 200680038075.2, dated Nov. 23, 2010. |
Office Action issued in New Zealand Patent Application No. 566773, dated Oct. 9, 2009. |
Office Action issued in New Zealand Patent Application No. 567891, dated Nov. 9, 2009. |
Office Action issued in Russian Application No. 2008110940, dated Jun. 11, 2010. |
Office Action issued in Russian Patent Application No. 2008122063, dated Oct. 5, 2010. |
Response to Office Action in U.S. Appl. No. 10/188,591, dated Jan. 19, 2006. |
Response to Office Action in U.S. Appl. No. 10/188,591, dated Mar. 13, 2006. |
Response to Office Action in U.S. Appl. No. 10/188,591, dated Sep. 1, 2006. |
Response to Office Action in U.S. Appl. No. 10/188,591, dated Sep. 26, 2006. |
Response to Office Action in U.S. Appl. No. 10/188,591, dated Mar. 15, 2007. |
Response to Office Action in U.S. Appl. No. 10/188,591, dated Sep. 28, 2007. |
Response to Office Action in U.S. Appl. No. 11/372,681, dated Nov. 27, 2006. |
Response to Office Action in U.S. Appl. No. 11/372,681, dated Jun. 25, 2007. |
Response to Office Action in U.S. Appl. No. 11/372,681, dated Nov. 26, 2007. |
Response to Office Action in U.S. Appl. No. 11/372,681, dated Mar. 20, 2008. |
Response to Office Action in U.S. Appl. No. 11/372,681, dated Aug. 1, 2008. |
Response to Office Action in U.S. Appl. No. 11/372,681, dated Dec. 18, 2008. |
Response to Office Action in U.S. Appl. No. 11/372,681, dated May 20, 2009. |
Response to Office Action in U.S. Appl. No. 11/372,681, dated Sep. 8, 2009. |
Response to Office Action in U.S. Appl. No. 11/372,681, dated Mar. 22, 2010. |
Response to Office Action in U.S. Appl. No. 11/372,681, dated Nov. 5, 2010. |
Response to Office Action in U.S. Appl. No. 11/372,681, dated Apr. 12, 2011. |
Response to Office Action in U.S. Appl. No. 11/466,349, dated Sep. 14, 2009. |
Response to Office Action in U.S. Appl. No. 11/466,349, dated Mar. 8, 2010. |
Response to Office Action in U.S. Appl. No. 11/482,265, dated Sep. 15, 2006. |
Response to Office Action in U.S. Appl. No. 11/482,265, dated Feb. 28, 2007. |
Response to Office Action in U.S. Appl. No. 11/482,265, dated Sep. 12, 2007. |
Response to Office Action in U.S. Appl. No. 11/482,265, dated Mar. 20, 2008. |
Response to Office Action in U.S. Appl. No. 11/482,265, dated Oct. 3, 2008. |
Response to Office Action in U.S. Appl. No. 11/482,265, dated Apr. 13, 2009. |
Response to Office Action in U.S. Appl. No. 11/482,265, dated Aug. 31, 2009. |
Response to Office Action in U.S. Appl. No. 11/482,265, dated Apr. 19, 2010. |
Response to Office Action in U.S. Appl. No. 11/482,265, dated Nov. 9, 2010. |
Response to Office Action in U.S. Appl. No. 11/482,265, dated Apr. 12, 2011. |
Response to Office Action in U.S. Appl. No. 11/483,218, dated Sep. 15, 2006. |
Response to Office Action in U.S. Appl. No. 11/483,218, dated Feb. 28, 2007. |
Response to Office Action in U.S. Appl. No. 11/483,218, dated May 10, 2007. |
Response to Office Action in U.S. Appl. No. 11/483,218, dated Aug. 4, 2008. |
Response to Office Action in U.S. Appl. No. 11/483,219, dated Sep. 15, 2006. |
Response to Office Action in U.S. Appl. No. 11/483,219, dated Feb. 28, 2007. |
Response to Office Action in U.S. Appl. No. 11/483,219, dated Sep. 12, 2007. |
Response to Office Action in U.S. Appl. No. 11/483,219, dated Mar. 20, 2008. |
Response to Office Action in U.S. Appl. No. 11/483,219, dated Oct. 3, 2008. |
Response to Office Action in U.S. Appl. No. 11/483,219, dated Apr. 13, 2009. |
Response to Office Action in U.S. Appl. No. 11/483,219, dated Aug. 31, 2009. |
Response to Office Action in U.S. Appl. No. 11/483,219, dated Apr. 19, 2010. |
Response to Office Action in U.S. Appl. No. 11/483,219, dated Nov. 9, 2010. |
Response to Office Action in U.S. Appl. No. 11/483,219, dated Apr. 12, 2011. |
Response to Office Action in U.S. Appl. No. 11/532,747, dated Mar. 20, 2008. |
Response to Office Action in U.S. Appl. No. 11/532,747, dated Aug. 4, 2008. |
Response to Office Action in U.S. Appl. No. 11/532,747, dated Mar. 9, 2009. |
Response to Office Action in U.S. Appl. No. 11/532,747, dated Jul. 17, 2009. |
Response to Office Action in U.S. Appl. No. 11/532,747, dated Mar. 22, 2010. |
Response to Office Action in U.S. Appl. No. 11/532,747, dated Sep. 30, 2010. |
Response to Office Action in U.S. Appl. No. 11/532,747, dated Apr. 12, 2011. |
Response to Office Action in U.S. Appl. No. 11/532,772, dated Mar. 12, 2009. |
Response to Office Action in U.S. Appl. No. 11/532,772, dated Sep. 8, 2009. |
Response to Office Action in U.S. Appl. No. 11/532,772, dated Mar. 23, 2010. |
Response to Office Action in U.S. Appl. No. 11/532,772, dated Oct. 28, 2010. |
Response to Office Action in U.S. Appl. No. 11/532,772, dated Apr. 11, 2011. |
Response to Office Action in U.S. Appl. No. 11/532,824, dated Jul. 1, 2009. |
Response to Office Action in U.S. Appl. No. 11/532,824, dated Mar. 22, 2010. |
Response to Office Action in U.S. Appl. No. 11/532,824, dated Oct. 12, 2010. |
Response to Office Action in U.S. Appl. No. 11/532,836, dated Mar. 20, 2008. |
Response to Office Action in U.S. Appl. No. 11/532,836, dated Aug. 4, 2008. |
Response to Office Action in U.S. Appl. No. 11/532,836, dated Dec. 17, 2008. |
Response to Office Action in U.S. Appl. No. 11/532,836, dated May 20, 2009. |
Response to Office Action in U.S. Appl. No. 11/532,836, dated Sep. 8, 2009. |
Response to Office Action in U.S. Appl. No. 11/532,836, dated Apr. 19, 2010. |
Response to Office Action in U.S. Appl. No. 11/532,836, dated Nov. 22, 2010. |
Response to Office Action in U.S. Appl. No. 11/532,836, dated Apr. 12, 2011. |
Response to Office Action in U.S. Appl. No. 11/532,845, dated Jul. 9, 2009. |
Response to Office Action in U.S. Appl. No. 11/532,845, dated Feb. 1, 2010. |
Response to Office Action in U.S. Appl. No. 11/532,858, dated Jul. 9, 2009. |
Response to Office Action in U.S. Appl. No. 11/532,858, dated Feb. 1, 2010. |
Response to Office Action in U.S. Appl. No. 11/592,719, dated Apr. 11, 2011. |
Response to Office Action in U.S. Appl. No. 12/042,206, dated Jan. 20, 2011. |
Response to Office Action in U.S. Appl. No. 12/042,212, dated Apr. 18, 2011. |
Response to Office Action, in U.S. Appl. No. 11/483,218, dated Jan. 7, 2009. |
Response to Office Action, in U.S. Appl. No. 11/483,218, dated Jan. 6, 2008. |
Selam and Charles, “Devices for insulin administration.” Diabetes Care, 13:955-79, 1990. |
Su et al., “The Relationship between Regimen Burden and Psychological Well Being in Persons with Type 1 Diabetes: Inhaled vs Injectable Insulin,” American Diabetes Association 62nd Annual Meeting and Scientific Sessions, San Francisco, CA, Jun. 14-18, 2002 (Abstract No. 1843-P, p. A448). |
Taddio et al., “Use of lidocaine-priolcaine cream for vaccination pain in infants,” J. Pediatr., 124:643-648, 1994. |
Testa et al., “Patient satisfaction with insulin therapy in type 2 diabetes: a randomized trial of injectable vs. inhaled insulin.” American Diabetes Association 62nd Annual Meeting and Scientific Sessions, Jun. 14-18, 2002, San Francisco, CA, US. |
Text of Office Action, in Japanese App. No. 2004-519654, dated Oct. 16, 2009. (English translation). |
Zambanini et al., “Injection related anxiety in insulin-treated diabetes.” Diabetes Res. Clin. Pract., 46:239-46, 1999. |
Office Communication issued in Mexican Patent Application No. MX/a/2012/009448, dated Feb. 25, 2014. (Machine Translation). |
Number | Date | Country | |
---|---|---|---|
20160015892 A1 | Jan 2016 | US |
Number | Date | Country | |
---|---|---|---|
60733311 | Nov 2005 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 13557026 | Jul 2012 | US |
Child | 14722106 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11592719 | Nov 2006 | US |
Child | 13557026 | US |